is retatrutide a glp 1 agonist What GLP‑3 Really Is: Triple‑Receptor Drug Some Providers Prescribe Unapproved Retatrutide

Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity

Indian J Gastroenterol

This precision helps your provider optimize your starting dose from day oneespecially valuable when you're balancing GLP-1 therapy with HRT, ensuring both treatments work harmoniously without unnecessary adjustments

Nausea is the most common side effect when first starting an injectable medication for weight loss

Xultophy 100/3.6 (active ingredients: insulin degludec and liraglutide) subcutaneous injection Initial FDA Approval: 2016 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting